Key contacts

Peter Molloy

Peter Molloy
Founding Director

Simon Bindloss

Simon Bindloss
Business Development Manager

Regional office - North America
295 Madison Avenue
18th Floor, New York
NY10017 United States

Tel: +1 646 653 7026

listed companies

Sunesis Pharmaceuticals GW Pharmaceuticals
TransAtlantic Petroleum Afferro Mining
South American Silver Corp Infinity Pharmaceuticals
Exelixis Idenix
Pharmacyclics Ariad Pharmaceuticals
Arrowhead Research Corporation AVEO Pharmaceuticals
Sangamo BioSciences TransDigm Group
Array BioPharma Alnylam Pharmaceuticals
Spirit AeroSystems FLIR Systems
BioCryst Pharmaceuticals BioLineRx
See more

Companies with HQs in usa

Photocure Caledonia Mining
Veris Gold Corp Nordgold
Ardea Biosciences CAE
Woulfe Mining RGI International
Altius Minerals Orbite Aluminae
Pan American Goldfields Nordion
Paladin Labs Dalradian Resources
Patheon Exact Sciences
MethylGene OPMEDIC Group
Torex Gold Canada Lithium Corporation
See more

Latest research

Pluristem Therapeutics

Grants and collaborations to support development

Update | Pharmaceutical & healthcare | 18/10/2017

Pluristem now has three ongoing clinical programs: critical limb ischemia (CLI, Phase III), intermittent claudication (IC, Phase II) and the acute radiation syndrome program (ARS, primates), which was recently expanded due to the participation of the US Department of Defense (DOD). Many of the costs of these programs have been offset, for instance due to NIH support of the ARS program as well as new grants of $16.6m to study PLX-PAD. The company recently received FDA and EMA sign-offs on a Phase…

Euromax Resources

Termination of coverage

Update | Mining | 16/10/2017

Edison Investment Research is terminating coverage on Euromax Resources (EOX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Orosur Mining

A new dawn cometh

Outlook | Mining | 10/10/2017

As Orosur Mining (OMI) continues to extend San Gregorio’s mine life (a raft of new exploration programmes seek to extend reserves by more than 100koz), the company recently sought additional funds to advance exploration at its very promising Anzá gold and base metals project in the highly prospective middle-caucus region of Colombia. With initial drilling to recommence shortly, historical exploration results highlight the area’s potential. We believe Anzá has the potential…

Cellular Biomedicine Group

Cell therapy for China and the US

Initiation | Pharmaceutical & healthcare | 02/10/2017

We are initiating coverage on Cellular Biomedicine Group (CBMG), a trans-Pacific cell therapy company developing products in China and the US. It has two ongoing Phase I clinical trials of CD19 chimeric antigen receptor T-cell (CAR-T) therapies for blood cancers in China. Additionally, it is adapting its knee osteoarthritis (KOA) treatment ReJoin as an allogeneic product, AlloJoin, which it hopes to develop in the US after a 2017 or 2018 IND. We arrive at an initial valuation of $191.6m or $13.58…

Sierra Oncology

Expanding on a proven class of anti-cancer drugs

Initiation | Pharmaceutical & healthcare | 18/09/2017

We are initiating coverage on Sierra Oncology, a drug developer targeting the DNA damage response (DDR) network to treat cancer. The company has two Phase I trials with SRA737 targeting checkpoint kinase 1 (Chk1) in patients with genetic tumor types expected to respond to the drug. Inhibition of Chk1 is lethal in cells with defective p53 (among others), one of the most common cancer mutations, and also enhances the response to chemotherapy. Sierra also has the cell division cycle 7 (Cdc7) inhibitor…

Edison North America

Edison’s North American office opened in 2011 to provide research services to companies listed on North American stock exchanges. Companies of all sizes benefit from our research service, which provides the highest standards of equity research and unrivalled distribution of our reports on a global and unrestricted basis.